HC / NOC · Health Canada
Notices of Compliance
Which drugs cleared regulatory approval this quarter, the indications behind each Notice of Compliance, and what is still queued in review.
The Access Dispatch Canadian Market Access Issue · Q2 2026
The quarter in Canadian market access
Health Canada NOCs, CDA-AMC reviews, INESSS recommendations, and pCPA negotiations across the access pathway — plus what U.S. most-favored-nation drug pricing means for Canada. A quarterly briefing from the RapidAccess.ai intelligence desk.
Send it to my inbox
FreeEnter your work email and we'll send a one-click link to confirm and open the report.
Check your inbox
We sent a link to open the report to
you@company.com
Click the link in that email to confirm and open it. It can take a minute to arrive — check spam if you don't see it.
One quick check
That looks like a personal address, so we'll confirm it before sending — usually within one business day.
Work emails open the report instantly — no waiting.
Otherwise we'll email your link to .
Request received
We review a small number of requests before sending. We'll email your access link to
Usually within one business day — nothing to do on your end.
You're in
Your email's already confirmed — open the report below.
Report Preview
RA·Q2·2026
- Agencies
- 4 in one view
- Coverage
- Full pathway
- Issue
- Q2 2026
In this issue
Four stages · one pathwayCDA-AMC · Canada's Drug Agency
Reimbursement reviews
National HTA recommendations — reimburse, reimburse with conditions, or do not reimburse — and the clinical and economic reasoning behind each call.
INESSS · Québec
Provincial evaluations
Where Québec's assessments diverged from the national picture, and the listings shaping access inside the province.
pCPA · pan-Canadian
Price negotiations
Where pan-Canadian negotiations opened, closed, or stalled — letters of intent signed, and the deals still on the table.
Spotlight
The U.S. MFN pricing wildcard
Most-favored-nation drug pricing is the variable that reshapes 2026 planning. The briefing maps the mechanics, the exposure it creates for Canadian list and net prices, and the scenarios worth modelling now — before they land in a negotiation.
For the people who turn approval into access
Market access, pricing, HEOR, and commercial leaders at pharma and biotech read this to stay ahead of the Canadian pathway — the reviews, listings, and negotiations that decide whether a therapy reaches patients, and on what terms.
Beyond the quarter
This briefing is a quarterly snapshot. The RapidAccess.ai platform is the live feed — CDA-AMC reviews, pCPA negotiations, and competitive dynamics as they move.
Book a demoIssue · Q2 2026
Get the Q2 2026 briefing
Every reimbursement decision that shaped the quarter, from approval to pricing. Straight to your inbox, free.
Get the report